Novel glutamatergic drugs for the treatment of mood disorders

Mood disorders are common and debilitating, resulting in a significant public health burden. Current treatments are only partly effective and patients who have failed to respond to trials of existing antidepressant agents (eg, those who suffer from treatment-resistant depression [TRD]) require innov...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapidus, Kyle AB, Soleimani, Laili, Murrough, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/
https://www.ncbi.nlm.nih.gov/pubmed/23976856
http://dx.doi.org/10.2147/NDT.S36689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/
https://www.ncbi.nlm.nih.gov/pubmed/23976856
http://dx.doi.org/10.2147/NDT.S36689

Ejemplares similares